We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

CRISPR/Cas9 Modified to Increase Its Versatility

By LabMedica International staff writers
Posted on 22 Jan 2019
Print article
Image: ProCas9 can sense the presence of an enzyme called a protease. ProCas9 (left, gray) is inactive until the protease snips a short piece of protein (red loop), at which point it becomes active (right, red) and binds DNA. By making the Cas9 fluoresce when it binds DNA, researchers get a signal that the protease is present (Photo courtesy of University of California, Berkeley).
Image: ProCas9 can sense the presence of an enzyme called a protease. ProCas9 (left, gray) is inactive until the protease snips a short piece of protein (red loop), at which point it becomes active (right, red) and binds DNA. By making the Cas9 fluoresce when it binds DNA, researchers get a signal that the protease is present (Photo courtesy of University of California, Berkeley).
A team of molecular biologists has modified the CRISPR/Cas9 gene-editing tool to incorporate an "on switch", which enables the precise manipulation of specific genes in selected cells.

CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation.

By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system from Streptococcus pyogenes is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand. Nonetheless, the CRISPR/Cas9 scaffold is not ideal for fusions or activation by cellular triggers.

To increase the versatility of the CRISPR/Cas9 protein scaffolding, investigators at the University of California, Berkeley (USA) used a circular permutation technique to show that a topological rearrangement of Cas9 would provide an advanced platform for RNA-guided genome modification and protection.

Circular permutation involved cutting the amino-acid string of the Cas9 protein, switching the order of the two segments, and then allowing it to fold into a new three-dimensional configuration. While this process frequently deactivated Cas9, the enzyme remained functional about 10% of the time.

The investigators found that the protein's termini could be positioned adjacent to bound DNA, offering a straightforward mechanism for strategically fusing functional domains. Additionally, circular permutation enabled protease-sensing Cas9s (ProCas9s), a unique class of single-molecule effectors possessing programmable inputs and outputs. ProCas9s could sense a wide range of proteases, and the investigators reported in the January 10, 2019, issue of the journal Cell that ProCas9 could orchestrate a cellular response to pathogen-associated protease activity.

"When we cut the protein and moved the old piece to a new place within the protein, the system became very sensitive to how you linked the two fragments together," said senior author Dr. David Savage, associate professor of molecular and cell biology at the University of California, Berkeley. "We realized that we could use that sensitivity to engineer the protein to have protease recognition sites. We are not stuck with what nature gave us with regards to genome-editing proteins. These proteins can be elaborately optimized and turned into scaffolds not found in nature but possessing the right properties for use in human cells. There are a lot of proteases that regulate signaling pathways in cells, transform normal cells into cancer cells, and are involved in pathogen infection. If we can sense these signals, we can tap into and respond accordingly to these important pathways."

Related Links:
University of California, Berkeley

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.